Recombinant adeno-associated virus (rAAV) technology pioneered by AskBio's Dr. Jude Samulski is key component of all FDA approved AAV gene therapeutics

Asklepios BioPharmaceutical, Inc. (AskBio), a wholly-owned and independently-operated subsidiary of Bayer AG, today announced that the FDA's approval of a new adeno-associated virus (AAV) gene therapy to treat adults with hemophilia B marks another milestone for the advancement of AAV therapeutics and highlights the important research contributions made by AskBio Co-Founder, President and Chief Scientific Officer, R. Jude Samulski, PhD.

from Breaking World Pharma News https://ift.tt/2KbGwT6